CHINARES PHARMA (03320) Subsidiary China Resources Double-Crane Gets Approval to Issue RMB 3 Billion Corporate Bonds

Stock News

Jan 26

CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the China Securities Regulatory Commission for its plan to issue corporate bonds to qualified investors in the People's Republic of China. The notice is valid for 24 months from the date of issuance, during which China Resources Double-Crane may issue corporate bonds in tranches with a total value of RMB 3 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1150835394"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150835394\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150835394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150835394","market":"fut","top_or_hot":-1,"title":"CHINARES PHARMA (03320) Subsidiary China Resources Double-Crane Gets Approval to Issue RMB 3 Billion Corporate Bonds","media":"Stock News","content":"<p>CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the China Securities Regulatory Commission for its plan to issue corporate bonds to qualified investors in the People's Republic of China.\nThe notice is valid for 24 months from the date of issuance, during which China Resources Double-Crane may issue corporate bonds in tranches with a total value of RMB 3 billion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA (03320) Subsidiary China Resources Double-Crane Gets Approval to Issue RMB 3 Billion Corporate Bonds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA (03320) Subsidiary China Resources Double-Crane Gets Approval to Issue RMB 3 Billion Corporate Bonds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-26 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the China Securities Regulatory Commission for its plan to issue corporate bonds to qualified investors in the People's Republic of China.\nThe notice is valid for 24 months from the date of issuance, during which China Resources Double-Crane may issue corporate bonds in tranches with a total value of RMB 3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1150835394","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150835394","pubTimestamp":1769434795,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","BK0028":"国家队","BK1570":"华润系","BK0185":"二线龙头","BK0239":"医药制造","BK1191":"制药","BK0188":"融资融券","03320":"华润医药","BK0175":"白马股","BK0010":"央企"},"translate_title":"CHINARES PHARMA(03320)附属华润双鹤获批发行30亿元人民币公司债券","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":1,"03320":1},"content_text":"CHINARES PHARMA (03320) announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has received a registration approval notice (No. 118 [2026]) from the China Securities Regulatory Commission for its plan to issue corporate bonds to qualified investors in the People's Republic of China.\nThe notice is valid for 24 months from the date of issuance, during which China Resources Double-Crane may issue corporate bonds in tranches with a total value of RMB 3 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}